Please login to the form below

Not currently logged in
Email:
Password:

Claes Buxfeldt joins NDA

He becomes its new HTA director

AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board.

During the past 18 years, Buxfeldt’s career has seen him work on a variety of disease areas, supporting more than 30 molecules/brands in global positions.

He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

Dr Werner Van den Eynde, vice president for the NDA advisory board, said: “We are very happy to welcome Claes on board as our new HTA director.

“Claes’ expertise will allow us to provide an even better service to our clients.”

Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA area.

21st March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...